Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients

Ma et al., AACR Annual Meeting 2022, Apr 2022

Review of the mechanisms of action of proxalutamide for COVID-19, and in vitro results showing that proxalutamide inhibited SARS-CoV-2 wild type, alpha and delta variants, with IC₅₀ of 69, 48 and 39nM. Only the abstract is currently available.

2 preclinical studies support the efficacy of proxalutamide for COVID-19:

2 in vitro studies1,2

Important missing comments or errors? Let us know.

1. Qiao et al., Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response, PNAS, doi:10.1073/pnas.222180912.pnas.org, doi.org.

2. Ma et al., Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients, AACR Annual Meeting 2022, www.abstractsonline.com/pp8/#!/10517/presentation/18533abstractsonline.com.

Ma et al., 8 Apr 2022, peer-reviewed, 12 authors.

In vitro studies are an important part of preclinical research, however results may be very different in vivo.